Mr Chee Khoon Lee

Clinical Lead
NHMRC Clinical Trials Centre, Sydney Medical School

Telephone +61 2 9562 5365

Map

Current research students

Project title Research student
Novel biomarkers to individualise treatment with targeted/biological therapies for advanced cancers Angelina TJOKROWIDJAJA

Selected grants

2017

  • Phase II clinical trial of the PARP inhibitor, olaparib, in HR- deficient advanced breast and ovarian cancer in women without inherited BRCA1 or BRCA2 mutations; Sjoquist K, Dobrovic A, Scott C, Mileshkin L, Wilcken N, Lee C; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2016

  • Genome-wide association study of single nucleotide polymorphisms as predictive biomarkers for sensitivity to anti-EGFR antibody therapy for metastatic colorectal cancer with wild-type RAS; Townsend A, Hardingham J, Gordon L, Lee C, Price T; Cancer Council South Australia/Beat Cancer Project Grant.

2015

  • The landscape of cancer genes and associations with prognosis in breast cancer diagnosed in premenopausal women; Coates A, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

2014

  • Does Palliative Chemotherapy Palliate Measuring symptom benefit in recurrent ovarian cancer using patient reported outcomes: The Symptom Benefit Study; Friedlander M, King M, Oza A, Ledermann J, O'Connell R, Sjoquist K, Martyn J, Lee C; National Health and Medical Research Council (NHMRC)/Project Grants.

2013

  • Technical services of a genomic cancer clinical trial initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols; Stockler M, Simes R, Vachan B, Sjoquist K, Lee C, Yip S; Cancer Australia/Request for Tender.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Lee, C., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R., Gralla, R., Mok, T., Yang, J. (2018). Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology, 4(2), 210-216. [More Information]
  • Ritchie, G., Gasper, H., Man, J., Lord, S., Marschner, I., Friedlander, M., Lee, C. (2018). Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis. JAMA Oncology, 4(4), 522-528. [More Information]
  • Gebski, V., Yang, J., Lee, C. (2018). Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncology, 4(8), 1138-1139. [More Information]
  • Ramalingam, S., Yang, J., Lee, C., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., et al (2018). Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(9), 841-849. [More Information]
  • Lee, C., Novello, S., Ryden, A., Mann, H., Mok, T. (2018). Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. Journal of Clinical Oncology, 36(18), 1853-1860. [More Information]
  • Elmadahm, A., Lord, S., Hudson, H., Lee, C., Buizen, L., Farshid, G., Gebski, V., Gill, P. (2018). Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. Breast, 41, 82-88. [More Information]
  • Sjoquist, K., Lord, S., Friedlander, M., Marschner, I., Lee, C., Simes, R. (2018). Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology, 10, 1-16. [More Information]
  • Friedlander, M., Rau, J., Lee, C., Meier, W., Lesoin, A., Kim, J., Poveda, A., Buck, M., Scambia, G., Shimada, M., King, M., et al (2018). Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial Measuring what matters - patient centered endpoints in trials of maintenance therapy. Annals of Oncology, 29(3), 737-743. [More Information]
  • Lee, C., Lord, S., Marschner, I., Wu, Y., Sequist, L., Rosell, R., Fukuoka, M., Mitsudomi, T., Asher, R., Davies, L., Gebski, V., et al (2018). The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 13(6), 792-800. [More Information]
  • Man, J., Ritchie, G., Links, M., Lord, S., Lee, C. (2018). Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. Asia-Pacific Journal of Clinical Oncology, 14(3), 141-152. [More Information]
  • Lee, C., Hudson, M., Simes, R., Ribi, K., Bernhard, J., Coates, A. (2018). When do patient reported quality of life indicators become prognostic in breast cancer? Health and Quality of Life Outcomes, 16(1), 13. [More Information]
  • Tjokrowidjaja, A., Chou, D., Baillie, T., Sivasubramaniam, R., Moses, J., Lee, C. (2017). A most malignant malady': a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma. Internal Medicine Journal, 47(10), 1215-1216. [More Information]
  • Lee, C., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., Yang, J. (2017). Checkpoint Inhibitors in Metastatic EGFR-Mutated Non�Small Cell Lung Cancer�A Meta-Analysis. Journal of Thoracic Oncology, 12(2), 403-407. [More Information]
  • Park, S., Kwok, J., Asher, R., Lee, C., Beale, P., Selle, F., Friedlander, M. (2017). Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology, 28(11), 2733-2740. [More Information]
  • Lee, C., Davies, L., Wu, Y., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., Lord, S., Marschner, I., Gebski, V., et al (2017). Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. Journal of the National Cancer Institute, 109(6), 1-13. [More Information]
  • Mok, T., Wu, Y., Ahn, M., Garassino, M., Kim, H., Ramalingam, S., Shepherd, F., He, Y., Akamatsu, H., Lee, C., et al (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. New England Journal of Medicine, 376(7), 629-640. [More Information]
  • Roncolato, F., Gibbs, E., Lee, C., Asher, R., Davies, L., Gebski, V., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M., King, M., et al (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology, 28(8), 1849-1855. [More Information]
  • Sorio, R., Roemer-Becuwe, C., Hilbert, F., Gibbs, E., Garcia, Y., Kaern, J., Huizing, M., Witteveen, P., Zagouri, F., Coeffic, D., Lee, C., Gebski, V., et al (2017). Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic Oncology, 144(1), 65-71. [More Information]
  • Ramalingam, S., Yang, J., Lee, C., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Janne, P. (2016). LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. Journal of Thoracic Oncology, 11(4S), S152-S152.
  • Lindemann, K., Kristensen, G., Mirza, M., Davies, L., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M., Raspagliesi, F., Lee, C., Gebski, V., et al (2016). Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. Annals of Oncology, 27(8), 1505-1510. [More Information]
  • Trillsch, F., Mahner, S., Hilpert, F., Davies, L., Garcia-Martinez, E., Kristensen, G., Savarese, A., Vuylsteke, P., Los, M., Zagouri, F., Gebski, V., Lee, C., et al (2016). Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Annals of Oncology, 27(9), 1733-1739. [More Information]
  • Ding, P., Lord, S., Gebski, V., Links, M., Bray, V., Gralla, R., Yang, J., Lee, C. (2016). Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non�Small Cell Lung Cancer. Journal of Thoracic Oncology, 12(4), 633-643. [More Information]
  • Lee, C., Davies, L., Gebski, V., Lord, S., Di Leo, A., Johnston, S., Geyer, C., Cameron, D., Press, M., Ellis, C., Marschner, I., Simes, R., et al (2016). Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer. Journal of Clinical Oncology, 34(9), 936-944. [More Information]
  • Vickers, M., Lee, C., Tu, D., Wheatley-Price, P., Parulekar, W., Brundage, M., Moore, M., Au, H., O'Callaghan, C., Jonker, D., et al (2016). Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology, 16(6), 1106-1112. [More Information]
  • Price, T., Bruhn, M., Lee, C., Hardingham, J., Townsend, A., Robledo, K., Simes, R., Weickhardt, A., Wrin, J., Wilson, C., Gebski, V., et al (2015). Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 112(6), 963-970. [More Information]
  • Lee, C., Goldstein, D., Gibbs, E., Joensuu, H., Zalcberg, J., Verweij, J., Casali, P., Maki, R., Cioffi, A., Lord, S., et al (2015). Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 51(7), 852-860. [More Information]
  • Lee, C., Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I., et al (2015). Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecologic Oncology, 136(1), 18-24. [More Information]
  • Lee, C., Wu, Y., Ding, P., Lord, S., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., Gebski, V., et al (2015). Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 33(17), 1958-1965. [More Information]
  • Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, R., Murone, C., Byth Wilson, K., Parry, M., Asadi, K., Scott, A., et al (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45. [More Information]
  • Hocking, C., Hardingham, J., Broadbridge, V., Wrin, J., Townsend, A., Tebbutt, N., Cooper, J., Ruszkiewicz, A., Lee, C., Price, T. (2014). Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer, 14(1), 1-7. [More Information]
  • Tjokrowidjaja, A., Lee, C., Houssami, N., Lord, S. (2014). Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Internal Medicine Journal, 44(8), 764-770. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1319. [More Information]
  • Bruhn, M., Townsend, A., Lee, C., Shivasami, A., Price, T., Wrin, J., Arentz, G., Tebbutt, N., Hocking, C., Cunningham, D., et al (2014). Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 135(3), 731-741. [More Information]
  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105(9), 595-605. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., et al (2013). Retroperitoneal sarcomas: A review of disease spectrum, radiological features, characterisation and management. Gynecologic Oncology, 130(2), 289-294. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]
  • Carter, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Lee, C., Marschner, I., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]
  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Parry, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]
  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]
  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Lee, C., Hadley, A., DeSilva, K., Smith, G., Goldstein, D. (2009). When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis. World Journal of Surgical Oncology, 7(8), 1-4. [More Information]
  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.

Conferences

  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.

2018

  • Lee, C., Man, J., Lord, S., Cooper, W., Links, M., Gebski, V., Herbst, R., Gralla, R., Mok, T., Yang, J. (2018). Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncology, 4(2), 210-216. [More Information]
  • Ritchie, G., Gasper, H., Man, J., Lord, S., Marschner, I., Friedlander, M., Lee, C. (2018). Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers a systematic review and meta-analysis. JAMA Oncology, 4(4), 522-528. [More Information]
  • Gebski, V., Yang, J., Lee, C. (2018). Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncology, 4(8), 1138-1139. [More Information]
  • Ramalingam, S., Yang, J., Lee, C., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., et al (2018). Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 36(9), 841-849. [More Information]
  • Lee, C., Novello, S., Ryden, A., Mann, H., Mok, T. (2018). Patient-Reported Symptoms and Impact of Treatment With Osimertinib Versus Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The AURA3 Trial. Journal of Clinical Oncology, 36(18), 1853-1860. [More Information]
  • Elmadahm, A., Lord, S., Hudson, H., Lee, C., Buizen, L., Farshid, G., Gebski, V., Gill, P. (2018). Performance of four published risk models to predict sentinel lymph-node involvement in Australian women with early breast cancer. Breast, 41, 82-88. [More Information]
  • Sjoquist, K., Lord, S., Friedlander, M., Marschner, I., Lee, C., Simes, R. (2018). Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Therapeutic Advances in Medical Oncology, 10, 1-16. [More Information]
  • Friedlander, M., Rau, J., Lee, C., Meier, W., Lesoin, A., Kim, J., Poveda, A., Buck, M., Scambia, G., Shimada, M., King, M., et al (2018). Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial Measuring what matters - patient centered endpoints in trials of maintenance therapy. Annals of Oncology, 29(3), 737-743. [More Information]
  • Lee, C., Lord, S., Marschner, I., Wu, Y., Sequist, L., Rosell, R., Fukuoka, M., Mitsudomi, T., Asher, R., Davies, L., Gebski, V., et al (2018). The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. Journal of Thoracic Oncology, 13(6), 792-800. [More Information]
  • Man, J., Ritchie, G., Links, M., Lord, S., Lee, C. (2018). Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. Asia-Pacific Journal of Clinical Oncology, 14(3), 141-152. [More Information]
  • Lee, C., Hudson, M., Simes, R., Ribi, K., Bernhard, J., Coates, A. (2018). When do patient reported quality of life indicators become prognostic in breast cancer? Health and Quality of Life Outcomes, 16(1), 13. [More Information]

2017

  • Tjokrowidjaja, A., Chou, D., Baillie, T., Sivasubramaniam, R., Moses, J., Lee, C. (2017). A most malignant malady': a rare case of laryngeal tuberculosis in epidermal growth factor receptor mutant lung adenocarcinoma. Internal Medicine Journal, 47(10), 1215-1216. [More Information]
  • Lee, C., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., Yang, J. (2017). Checkpoint Inhibitors in Metastatic EGFR-Mutated Non�Small Cell Lung Cancer�A Meta-Analysis. Journal of Thoracic Oncology, 12(2), 403-407. [More Information]
  • Park, S., Kwok, J., Asher, R., Lee, C., Beale, P., Selle, F., Friedlander, M. (2017). Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial. Annals of Oncology, 28(11), 2733-2740. [More Information]
  • Lee, C., Davies, L., Wu, Y., Mitsudomi, T., Inoue, A., Rosell, R., Zhou, C., Nakagawa, K., Thongprasert, S., Fukuoka, M., Lord, S., Marschner, I., Gebski, V., et al (2017). Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival. Journal of the National Cancer Institute, 109(6), 1-13. [More Information]
  • Mok, T., Wu, Y., Ahn, M., Garassino, M., Kim, H., Ramalingam, S., Shepherd, F., He, Y., Akamatsu, H., Lee, C., et al (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. New England Journal of Medicine, 376(7), 629-640. [More Information]
  • Roncolato, F., Gibbs, E., Lee, C., Asher, R., Davies, L., Gebski, V., Friedlander, M., Hilpert, F., Wenzel, L., Stockler, M., King, M., et al (2017). Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy. Annals of Oncology, 28(8), 1849-1855. [More Information]
  • Sorio, R., Roemer-Becuwe, C., Hilbert, F., Gibbs, E., Garcia, Y., Kaern, J., Huizing, M., Witteveen, P., Zagouri, F., Coeffic, D., Lee, C., Gebski, V., et al (2017). Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic Oncology, 144(1), 65-71. [More Information]

2016

  • Ramalingam, S., Yang, J., Lee, C., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Janne, P. (2016). LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts. Journal of Thoracic Oncology, 11(4S), S152-S152.
  • Lindemann, K., Kristensen, G., Mirza, M., Davies, L., Hilpert, F., Romero, I., Ayhan, A., Burges, A., Rubio, M., Raspagliesi, F., Lee, C., Gebski, V., et al (2016). Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial. Annals of Oncology, 27(8), 1505-1510. [More Information]
  • Trillsch, F., Mahner, S., Hilpert, F., Davies, L., Garcia-Martinez, E., Kristensen, G., Savarese, A., Vuylsteke, P., Los, M., Zagouri, F., Gebski, V., Lee, C., et al (2016). Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial. Annals of Oncology, 27(9), 1733-1739. [More Information]
  • Ding, P., Lord, S., Gebski, V., Links, M., Bray, V., Gralla, R., Yang, J., Lee, C. (2016). Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non�Small Cell Lung Cancer. Journal of Thoracic Oncology, 12(4), 633-643. [More Information]
  • Lee, C., Davies, L., Gebski, V., Lord, S., Di Leo, A., Johnston, S., Geyer, C., Cameron, D., Press, M., Ellis, C., Marschner, I., Simes, R., et al (2016). Serum human epidermal growth factor 2 extracellular domain as a predictive biomarker for lapatinib treatment efficacy in patients with advanced breast cancer. Journal of Clinical Oncology, 34(9), 936-944. [More Information]
  • Vickers, M., Lee, C., Tu, D., Wheatley-Price, P., Parulekar, W., Brundage, M., Moore, M., Au, H., O'Callaghan, C., Jonker, D., et al (2016). Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology, 16(6), 1106-1112. [More Information]

2015

  • Price, T., Bruhn, M., Lee, C., Hardingham, J., Townsend, A., Robledo, K., Simes, R., Weickhardt, A., Wrin, J., Wilson, C., Gebski, V., et al (2015). Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 112(6), 963-970. [More Information]
  • Lee, C., Goldstein, D., Gibbs, E., Joensuu, H., Zalcberg, J., Verweij, J., Casali, P., Maki, R., Cioffi, A., Lord, S., et al (2015). Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. European Journal of Cancer, 51(7), 852-860. [More Information]
  • Lee, C., Lord, S., Grunewald, T., Gebski, V., Hardy-Bessard, A., Sehouli, J., Woie, K., Heywood, M., Schauer, C., Vergote, I., et al (2015). Impact of secondary cytoreductive surgery on survival in patients with platinum sensitive recurrent ovarian cancer: Analysis of the CALYPSO trial. Gynecologic Oncology, 136(1), 18-24. [More Information]
  • Lee, C., Wu, Y., Ding, P., Lord, S., Inoue, A., Zhou, C., Mitsudomi, T., Rosell, R., Pavlakis, N., Links, M., Gebski, V., et al (2015). Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology, 33(17), 1958-1965. [More Information]
  • Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, R., Murone, C., Byth Wilson, K., Parry, M., Asadi, K., Scott, A., et al (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45. [More Information]

2014

  • Hocking, C., Hardingham, J., Broadbridge, V., Wrin, J., Townsend, A., Tebbutt, N., Cooper, J., Ruszkiewicz, A., Lee, C., Price, T. (2014). Can we accurately report PTEN status in advanced colorectal cancer? BMC Cancer, 14(1), 1-7. [More Information]
  • Tjokrowidjaja, A., Lee, C., Houssami, N., Lord, S. (2014). Metastatic breast cancer in young women: a population-based cohort study to describe risk and prognosis. Internal Medicine Journal, 44(8), 764-770. [More Information]
  • Stockler, M., Hilpert, F., Friedlander, M., King, M., Wenzel, L., Lee, C., Joly, F., de Gregorio, N., Arranz, J., Mirza, M., et al (2014). Patient-Reported Outcome Results From the Open-Label Phase III AURELIA Trial Evaluating Bevacizumab-Containing Therapy for Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology, 32(13), 1309-1319. [More Information]
  • Bruhn, M., Townsend, A., Lee, C., Shivasami, A., Price, T., Wrin, J., Arentz, G., Tebbutt, N., Hocking, C., Cunningham, D., et al (2014). Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 135(3), 731-741. [More Information]

2013

  • Lee, C., Simes, R., Brown, C., Gebski, V., Pfisterer, J., Swart, A., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I., Lord, S., et al (2013). A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology, 24(4), 937-943. [More Information]
  • Lee, C., Brown, C., Gralla, R., Hirsh, V., Thongprasert, S., Tsai, C., Tan, E., Ho, J., Chu, D., Zaatar, A., Gebski, V., et al (2013). Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis. Journal of the National Cancer Institute, 105(9), 595-605. [More Information]
  • Fox, P., Hudson, M., Brown, C., Lord, S., Gebski, V., de Souza, P., Lee, C. (2013). Markers of systemic inflammation predict survival in patients with advanced renal cell cancer. British Journal of Cancer, 109(1), 147-153. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., Weickhardt, A., Simes, R., Murone, C., Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285. [More Information]
  • You, B., Colomban, O., Heywood, M., Lee, C., Davy, M., Reed, N., Pignata, S., Varsellona, N., Emons, G., Rehman, K., et al (2013). Retroperitoneal sarcomas: A review of disease spectrum, radiological features, characterisation and management. Gynecologic Oncology, 130(2), 289-294. [More Information]
  • Lee, C., Gebski, V., Coates, A., Veillard, A., Harvey, V., Tattersall, M., Byrne, M., Brigham, B., Forbes, J., Simes, R. (2013). Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone. SpringerPlus, 2(391), 1-10. [More Information]

2012

  • Carter, H., Lord, S., Martin, A., Gill, G., Lee, C., Howard, K., Wetzig, N., Simes, R. (2012). Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis. British Journal of Cancer, 106(6), 1045-1052. [More Information]
  • Lee, C., Marschner, I., Simes, R., Voysey, M., Egleston, B., Hudes, G., de Souza, P. (2012). Increase in Cholesterol PredictsSsurvival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research, 18(11), 3188-3196. [More Information]

2011

  • Lee, C., Hudson, M., Stockler, M., Coates, A., Ackland, S., Gebski, V., Lord, S., Friedlander, M., Boyle, F., Simes, R. (2011). A nomogram to predict survival time in women starting first-line chemotherapy for advanced breast cancer. Breast Cancer Research and Treatment, 129(2), 467-476. [More Information]
  • Lee, C., Gurney, H., Brown, C., Sorio, R., Donadello, N., Tulunay, G., Meier, W., Bacon, M., Maenpaa, J., Petru, E., Gebski, V., Lord, S., Simes, R., et al (2011). Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 105(3), 360-365. [More Information]
  • Lee, C., Friedlander, M., Brown, C., Gebski, V., Georgoulopoulos, A., Vergote, I., Pignata, S., Donadello, N., Schmalfeldt, B., Delva, R., Lord, S., Simes, R., et al (2011). Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian Cancer. Journal of the National Cancer Institute, 103(17), 1338-1342. [More Information]
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Parry, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Lee, C., Simes, R., Brown, C., Lord, S., Wagner, U., Plante, M., Vergote, I., Pisano, C., Parma, G., Burges, A., Gebski, V., et al (2011). Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer. British Journal of Cancer, 105(8), 1144-1150. [More Information]

2010

  • Lee, C., Lord, S., Stockler, M., Coates, A., Gebski, V., Simes, R. (2010). Historical cross-trial comparisons for competing treatments in advanced breast cancer - An empirical analysis of bias. European Journal of Cancer, 46(3), 541-548. [More Information]
  • Kiely, B., Lee, C., Tattersall, M., Stockler, M. (2010). How long have I got? Estimating post-progression survival after first line chemotherapy for metastatic breast cancer based on data from randomized trials. 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium.
  • Lee, C., Stockler, M., Coates, A., Gebski, V., Lord, S., Simes, R. (2010). Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. British Journal of Cancer, 102(9), 1341-1347. [More Information]

2009

  • Lee, C., Lord, S., Coates, A., Simes, R. (2009). Molecular biomarkers to individualise treatment: assessing the evidence. Medical Journal of Australia, 190(11), 631-636. [More Information]
  • Chua, W., Goldstein, D., Lee, C., Dhillon, H., Michael, M., Mitchell, P., Clark, S., Iacopetta, B. (2009). Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. British Journal of Cancer, 101(6), 998-1004. [More Information]
  • Lee, C., Hadley, A., DeSilva, K., Smith, G., Goldstein, D. (2009). When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis. World Journal of Surgical Oncology, 7(8), 1-4. [More Information]

2008

  • Lord, S., Lee, C., Simes, R. (2008). The Role of Predictive and Prognostic Markers in Cancer. Cancer Forum, 32(3), 139-142.

To update your profile click here. For support on your academic profile contact .